Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
161Tb-PNT6555
- Development stage
- Preclinical
- Lead developer
- POINT Biopharma
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
161Tb-PNT6555 is a radiopharmaceutical theranostic agent developed by POINT Biopharma (now a subsidiary of Eli Lilly) for the treatment of solid tumors expressing fibroblast activation protein-alpha (FAP). The agent consists of a FAP-targeting small molecule ligand (Bz-D-Ala-boroPro) conjugated to a DOTA chelator and radiolabeled with the isotope terbium-161. FAP is a transmembrane glycoprotein highly upregulated on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of many epithelial cancers, making it a pan-cancer target. Terbium-161 is a unique radionuclide that emits both beta particles and Auger electrons; the latter provide high linear energy transfer over a very short range, which may enhance therapeutic efficacy against small tumor clusters and micrometastases compared to traditional beta-emitters like lutetium-177.
- Other names
- 161Tb-labeled PNT6555terbium-161 PNT6555terbium161 PNT6555terbium 161 PNT6555
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 161Tb-PNT6555.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 161Tb-PNT6555.